EpiCast Report: Type 2 Diabetes - Epidemiology Forecast to 2026
Type 2 diabetes (T2D), formerly known as non-insulin dependent diabetes mellitus or adult-onset diabetes mellitus, is a chronic disorder of glucose equilibrium that results from the body’s inability to make use of available insulin along with relative insulin deficiency (WHO, 2016a). T2D constitutes approximately 90-95% of all diabetes cases around the world while, type 1 diabetes (T1D) and gestational diabetes make up the remaining 5-10% of the cases (CDC, 2011; CDC, 2014b; IDF, 2014).
The prevalence of diabetes is expected to grow rapidly as it is associated with aging populations, increasing urbanization, economic development, and the increase in the prevalence of risk factors like obesity, unhealthy dietary habits, and physical inactivity (IDF, 2015). Globally, diabetes will likely be the seventh-leading cause of death in the world by 2030 (Mathers and Loncar, 2006). Additionally, poorly managed diabetes leads to serious complications such as heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage. Diabetes also increases the risk of fetal death and other complications during pregnancy (WHO, 2016b).
In the 7MM, our epidemiologists forecast an increase in the diagnosed prevalent cases of T2D from 56,060,328 diagnosed prevalent cases in 2016 to 77,823,223 diagnosed prevalent cases in 2026, with an annual growth rate (AGR) of 3.88% during the forecast period. The US will have the highest number of diagnosed prevalent cases of T2D among the 7MM throughout the forecast period, while Italy will have the lowest.0
The report EpiCast Report: Type 2 Diabetes - Epidemiology Forecast to 2026 provides an overview of the risk factors, comorbidities, and the global and historical trends for T2D in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) and also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of T2D segmented by age (for ages 20 years and older) and sex in these markets. Additionally, the report provides a forecast of the major comorbidities of T2D, such as chronic kidney disease, cardiovascular disease, obesity, hypertension, and dyslipidemia in the diagnosed T2D prevalent pool.